Crispr Therapeutics Ag (CRSP) Stock Price & Analysis
Crispr Therapeutics Ag (CRSP) fell 0.23% to USD 51.48 as of June 9, 2026 at 23:36 UTC, according to Nexqual real-time market data.
CRSP last closed at USD 51.6; the session ranged USD 49.58–53.09 on volume of 1,457,021 shares. Market capitalization is $5.07B, with a 52-week range of USD 39.81–78.48 (NGM). Source: Nexqual, June 9, 2026 at 23:36 UTC.
Key Statistics (as of June 9, 2026 at 23:36 UTC)
| Price | USD 51.48 |
|---|---|
| Change | ▼ 0.23% (down) |
| Previous Close | USD 51.6 |
| Open | USD 52.55 |
| Day Range | USD 49.58 – 53.09 |
| 52-Week Range | USD 39.81 – 78.48 |
| Volume | 1,457,021 shares |
| Market Cap | $5.07B |
| Exchange | NGM |
Technical Analysis (CRSP)
Nexqual's technical model rates CRSP "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 9, 2026 at 23:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.12 (neutral) |
| vs SMA50 | Below (USD 52.34) |
| MACD | 0.17 (positive) |
Analyst Ratings (CRSP)
Wall Street analysts rate CRSP "Buy" based on 21 analysts, with a mean price target of USD 82.24 (range USD 33–291), per Nexqual as of June 9, 2026 at 23:36 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 82.24 |
| High Target | USD 291 |
| Low Target | USD 33 |
| Buy / Hold / Sell | 15 / 9 / 1 |
Earnings (CRSP)
| Next Earnings Date | 2026-05-11 |
|---|---|
| EPS Estimate | USD -1.18 |
| Revenue Estimate | $6.42M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.28 vs est -1.23 ▼ miss |
| 2025-12-31 | USD -1.37 vs est -1.23 ▼ miss |
| 2025-09-30 | USD -1.17 vs est -1.29 ▲ beat |
| 2025-06-30 | USD -1.29 vs est -1.4 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:36 UTC.
Financials & Fundamentals (CRSP)
| Total Revenue | $4.10M |
|---|---|
| Revenue Growth (YoY) | +68.60% |
| Gross Margin | +0.00% |
| Operating Margin | -8933.33% |
| Profit Margin | +0.00% |
| ROE | -31.21% |
| Debt / Equity | 43.41 |
| Current Ratio | 17.97 |
| Total Cash | $2.44B |
| Total Debt | $787.64M |
| Free Cash Flow | $-260.90M |
Source: Nexqual, June 9, 2026 at 23:36 UTC.
Financial Health Score (CRSP)
Nexqual rates Crispr Therapeutics Ag's overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:36 UTC.
| Growth | Critical — Revenue -91% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $2.44B cash vs $788M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$261M, burning cash |
| Efficiency | Critical — ROE -31%, ROA -14.1% |
Ownership (CRSP)
| Insider Ownership | +5.91% |
|---|---|
| Institutional Ownership | +79.20% |
| Shares Outstanding | 98.48M |
| Float | 96.03M |
| Short % of Float | +32.41% |
Source: Nexqual, June 9, 2026 at 23:36 UTC.
Leadership (CRSP)
Crispr Therapeutics Ag is led by Samarth Kulkarni (age 47), CEO & Chairman, per Nexqual as of June 9, 2026 at 23:36 UTC.
| CEO & Chairman | Samarth Kulkarni (age 47) |
|---|---|
| Chief Financial Officer | Raju Yashaswi Prasad (age 41) |
Major Backers & Investors (CRSP)
Notable institutional backers of Crispr Therapeutics Ag include ARK Invest, Orbis Allan Gray Ltd, Capital Group, according to Nexqual as of June 9, 2026 at 23:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 20.33% |
| Orbis Allan Gray Ltd | 6.33% |
| Capital Group | 4.9% |
| T. Rowe Price | 4.15% |
| GSK plc | 3.34% |
| SR One Capital Management, LP | 2.11% |
| FMR, LLC | 2.03% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.19% |
| State Street | 6.1% |
| Geode Capital | 2.46% |
Source: Nexqual, June 9, 2026 at 23:36 UTC.
From Crispr Therapeutics Ag's Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- For example, we have developed a proprietary, next-generation, site-specific gene correction platform called SyNTase editing.
- To turn this promise into reality, we have built a broad and diversified pipeline of product candidates leveraging gene-based technologies, including CRISPR/Cas9 gene editing technology. 4   Our Pipeline The following table summarizes the status of our product development pipeline: Hemoglobinopathies Hemoglobinopathies are a diverse group of inherited blood disorders that result from variations in the synthesis or structure of hemoglobin.
- We continue to innovate on our platform to develop next-generation technologies that can enable new therapies.
- We believe that our innovative research, translational expertise, and clinical development experience, position us as a leader in the development of CRISPR-based therapeutics and may enable us to create an entirely new class of highly effective and potentially curative therapies for patients with both common and rare diseases for whom current biopharmaceutical approaches have had limited success.
Partnerships
- CASGEVY is the first therapy to emerge from our strategic partnership with Vertex and is being advanced under a joint development and commercialization agreement between us and Vertex and certain of its affiliates.
- We are also pursuing additional delivery technologies, including LNPs, for delivery to tissues beyond the liver, including hematopoietic stem cells and T cells. siRNA-based Programs Our siRNA-based portfolio includes clinical-stage programs in cardiovascular and thromboembolic diseases, developed in collaboration with Sirius Therapeutics and certain of its affiliates, or Sirius.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | USD 12.89 | ▼ 4.8% |
| EDIT | Editas Medicine, Inc. | USD 2.65 | ▼ 2.21% |
| TDOC | Teladoc Health, Inc. | USD 6.93 | ▼ 1.7% |
| BEAM | Beam Therapeutics Inc. | USD 30.47 | ▲ 3.64% |
| PACB | Pacific Biosciences of Californ | USD 1.37 | ▼ 5.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:36 UTC. This page is informational and not investment advice.